RxCelerate acquires specialist bioanalytical CRO

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/oatwa)
(Image: Getty/oatwa)
UK-headquartered RxCelerate has acquired the specialist bioanalytical contract research organization Total Scientific – increasing its staff to 37 following its expansion stateside in November 2017.

RxCelerate, which provides outsourced drug discovery and development services, has offices in Cambridge, UK, and Cambridge, MA.

The deal – financial details of which were not disclosed – will see RxCelerate’s staff increase to 37, with the addition of Total Scientific’s 11 employees.

Total Scientific is located in Cambridge, UK at the Babraham Research Campus and specializes in measuring complex drugs and proteins in biological samples.

Effective immediately, the Total Scientific brand will be retired and all services will be offered through RxCelerate.

“Total Scientific was the first company in the world to offer Phenome-wide Association Studies (PheWAS) as a commercial service, underpinning their status as global leaders in highly specialized bioanalysis”​ said Dr. Jill Reckless, CEO of RxCelerate, in a press release.

“This capability, coupled with their GLP-compliant bioanalysis platform significantly extends the range of cutting-edge capabilities available to our clients to move their projects more efficiently to the next value inflection point.”

RxCelerate has not responded to a request for comment.


RxCelerate in November 2017 opened its offices in Massachusetts​ to expand its medicinal chemistry, antibody discovery, and preclinical safety services throughout North America.

The company’s executive vice president of US operations, Laura Hamilton, told us at the time that the move aims to establish long-term working relationships with biopharmaceutical firms in the "established and organized"​ area.

“We have worked with several clients in the US and are confident that we can grow our footprint in the North American market,”​ she explained.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more